Celyad Oncology SA

Biotechnology valuations generally have been on the rise in recent months, relative to general stock market indices, but there still are a number of drug developers that are having trouble gaining tra

The US Food and Drug Administration has placed a hold on Beam Therapeutics ’s preclinical candidate, BEAM-201. It is the latest in a string of off-the-shelf cell therapies to be placed on hold by the

Cell, gene and RNA therapies have been widely adopted by the major pharma players. While their growth is tremendous (52% CAGR up to 2026), they will only account for up to 7% of total market size by 2

With understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the com